Chemcrux Enterprises
- Market cap
- ₹ 116 Cr.
- P/E
- 29.3x
- P/B
- 1.52x
- 52-week range
- 71.8 – 91.45
- ROE
- 5%
- ROCE
- 7.4%
- Dividend yield
- 1.3%
- Debt / equity
- 0.45
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- NSE, BSE
About
Chemcrux Enterprises Limited is an India-based company. The Company is engaged in the business of manufacturing or processing of bulk drug intermediates like para chloro benzoic, ortho benzoic acid, and lasamide, and others. The Company's products include 2-Chloro Benzoic Acid, 3-Chloro Benzoic Acid, 4-Chloro Benzoic Acid, 2,4-Dichloro Benzoic Acid, 4-Chloro 3-Nitro Benzoic Acid; 2-Chloro 5-Nitro Benzoic Acid; Meta Nitro Benzoic Acid; Lasamide, and Meta Chloro Per Benzoic Acid, Para Chloro Benzoyl Chloride, Ortho Chloro Benzoyl Chloride, 2,4-Dichloro Benzoyl Chloride, 2,3-Dichloro Benzoyl Chloride. It is engaged in the development and execution of various processes, such as High-Pressure Oxidation, Nitration, Amidation, BPEA Sulfonamide and Chlorosulfonation. The Company caters to both the domestic and international markets. The Company’s manufacturing facility is located in Bharuch, Gujarat, India.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Chemcrux Enterprises against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)29.3 against a typical 25.8: pricier than most peers (1st = cheapest).72nd of 129
- Sales growth+33% against a typical +25.9% from a year earlier.43rd of 112
- Profit growth+466.7% against a typical +42.4% from a year earlier.8th of 102
- Size₹ 115.8 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).89th of 126
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16 | 22 | 19 | 17 | 18 | 19 | 16 | 17 | 18 | 22 | 24 | 22 |
| Expenses | 14 | 17 | 16 | 15 | 15 | 17 | 14 | 15 | 16 | 19 | 20 | 19 |
| Operating Profit | 2 | 4 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 4 | 4 | 3 |
| OPM % | 14.8% | 20.1% | 14.1% | 12% | 13.3% | 13.9% | 13.4% | 9.9% | 10.1% | 16% | 17.2% | 12.3% |
| Other Income | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 4 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 3 | 1 |
| Tax % | 30.2% | 36.8% | 3.5% | 29.6% | 26.3% | 25.8% | 68.7% | −233.3% | 46.2% | 28% | 30.7% | 48.5% |
| Net Profit | 1 | 3 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 2 | 1 |
| EPS in Rs | 0.84 | 1.8 | 1.49 | 0.84 | 0.78 | 0.89 | 0.14 | 0.06 | 0.14 | 1.07 | 1.25 | 0.34 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −5%
- TTM
- 24%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −36%
- TTM
- 50%
- 10 Years
- —
- 5 Years
- −9%
- 3 Years
- −35%
- TTM
- —
- 10 Years
- —
- 5 Years
- 13%
- 3 Years
- 7%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Chemcrux Enterprises | ₹ 81.75 | ₹ 116 Cr. | 29.3x | 1.5x | 5% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 39.3x | 5.7x | 14.2% | 19.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 74.8x | 19.8x | 27.1% | 15.3% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 75.1x | 11.8x | 16.2% | 24.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.1x | 3.4x | — | 11.9% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.4x | 4.1x | 19.7% | 18.5% |
Management
- Girishkumar C. Shah
- Executive Chairman of the Board
- Mruga Gajjar
- Chief Financial Officer
- Dipika Kumar Rajpal
- Company Secretary, Compliance Officer
- Sanjaybhai Y. Marathe
- Managing Director, Executive Director
- Vipul Pramodchandra Sanghvi
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.